In this video, Glen Curran, vice president anterior segment U.S. for Allergan, discusses the unmet need a therapeutic drop for the correction of presbyopia could potentially fulfill.
Allergan has submitted a new drug application for its investigational presbyopia treatment and expects action on the NDA from the FDA by the end of the year.
The NDA for AGN-190584 (pilocarpine 1.25%) ophthalmic solution is based on data from two phase 3 studies, according to a press release. GEMINI 1 and GEMINI 2 evaluated efficacy, safety and tolerability of the solution.
“If (Read more...)
Uncategorized